Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
Open Access
- 15 August 2013
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 122 (7) , 1293-1304
Abstract
Key Points: Targeting RAD52 DNA binding domain I by peptide aptamer induces synthetic lethality in BRCA-deficient leukemias. Individual patients with BRCA-deficient leukemias could be identified by genetic and epigenetic profiling.Keywords
This publication has 50 references indexed in Scilit:
- Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cellsNature, 2009
- BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death thresholdLeukemia, 2008
- Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repairCancer Letters, 2008
- Identification of a Second DNA Binding Site in the Human Rad52 ProteinJournal of Biological Chemistry, 2008
- DNA repair pathways as targets for cancer therapyNature Reviews Cancer, 2008
- Inference of Macromolecular Assemblies from Crystalline StateJournal of Molecular Biology, 2007
- Identification of Residues Important for DNA Binding in the Full-length Human Rad52 ProteinJournal of Molecular Biology, 2005
- Human rad51 amino acid residues required for rad52 bindingJournal of Molecular Biology, 1999
- Radiation-induced Assembly of Rad51 and Rad52 Recombination Complex Requires ATM and c-AblJournal of Biological Chemistry, 1999
- Rad51‐deficient vertebrate cells accumulate chromosomal breaks prior to cell deathThe EMBO Journal, 1998